Safe and effective variability-A criterion for dose individualization

Therapeutic Drug Monitoring

Volumn 34, Issue 5, 2012, Pages 565-568

  Holford, Nicholas H G ^a   Buclin, Thierry ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

dose individualization; parameter variability; population pharmacokinetics; safe and effective variability; target concentration intervention; therapeutic drug monitoring

Indexed keywords

ARTEMISININ; FELODIPINE; FENOTEROL; METOPROLOL; MOXONIDINE; RILUZOLE;

ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG MONITORING; PRIORITY JOURNAL;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACEUTICAL PREPARATIONS;

EID: 84866527108     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31826aabc3     Document Type: Article

References (17)

1. Wikipedia. Therapeutic drug monitoring. Available at: http://en.wikipedia. org/wiki/Therapeutic-drug-monitoring. Accessed August 8, 2012.
2. Pippenger CE. Therapeutic drug monitoring: an overview. Ther Drug Monit. 1979;1:3-9.
3. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52:5-9.
4. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol. 1999;48:9-13.
5. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6:429-453.
6. Sheiner L, Tozer T. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon K, Morelli H, eds. Clinical Pharmacology: Basic Principles of Therapeutics. New York: Macmillan; 1978:71-109.
7. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-332.
8. Sheiner LB, Rosenburg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5:445-479.
9. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol. 2004;58:8-19.
10. Lunn D, Aarons L. Markov Chain Monte Carlo techniques for studying interoccasion and intersubject variability: application to pharmacokinetic data. Appl Statist. 1997;46:73-91.
11. Bouillon T, Meineke I, Port R, et al. Concentration-effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age. Eur J Clin Pharmacol. 1996;51:153-160.
12. Bruno R, Vivier N, Libouix AL, et al. Population pharmacokinetics of riluzole in patients with amuyotrophic lateral sclerosis. Clin Pharmacol Ther. 1997;62:518-526.
13. Wade JR, Sambol NC. Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. Clin Pharmacol Ther. 1995;57:569-581.
14. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharm Biopharm. 1993;21:735-750.
15. Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharma-cokinet Biopharm. 1996;24:245-263.
16. Karlsson MO, Jonsson NE, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of mox-onidine data from congestive heart failure patients. J Pharm Biopharm. 1998;26:207-246.
17. Sidhu J, Ashton M. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol. 1998;45:347-354.